Quick Answer
Gossamer Bio, Inc. reported Revenue (ASC 606) of $48.47 million for fiscal year 2025.
Gossamer Bio, Inc. Revenue (ASC 606) — Annual History
| Fiscal Year | Revenue (ASC 606) | YoY Change |
|---|---|---|
| 2025 | $48.47M | -57.7% |
| 2024 | $114.70M | — |
| 2023 | $0.00 | — |
| 2022 | $0.00 | — |
Quarterly Revenue (ASC 606)
| Quarter Ending | Revenue (ASC 606) | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $13.29M | +40.2% | +15.7% |
| June 30, 2025 | $11.49M | -88.0% | +16.2% |
| March 31, 2025 | $9.89M | — | +4.3% |
| September 30, 2024 | $9.48M | — | -90.1% |
| June 30, 2024 | $95.84M | — | — |
| March 31, 2024 | $0.00 | — | — |
| September 30, 2023 | $0.00 | — | — |
| June 30, 2023 | $0.00 | — | — |
- Gossamer Bio, Inc. showed a decrease of -57.7% in Revenue (ASC 606) compared to the prior fiscal year.
- The most recent figure is from Gossamer Bio, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 17, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: